Abstract
Topical FK506 has recently been shown to have an anti-inflammatory effect in vivo in humans. In this study its effects in contact dermatitis were studied in the guinea pig model. Topical FK506 suppressed both irritant and allergic patch-test reactions. The most prominent suppressive effect was seen when skin sites were pretreated with FK506. Topical FK506 did not impair the induction of contact allergy as assessed by challenges, although it suppressed local lymph node cell accumulation during contact allergy induction. Topical FK506 may hold promise as a treatment for skin disorders that respond to oral FK506 or cyclosporin A.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Groisser DS, Griffiths CEM, Ellis CN, Voorhees JJ (1992) A review and update of the clinical uses of cyclosporine in dermatology. Dermatol Clin 9: 805–817
Griffiths CEM, Powles AV, Baker BS, Fry L, Valdimarsson H (1987) Topical cyclosporine and psoriasis. Lancet I: 806
Reitamo S, KÄyhkö K, Lauerma AI, Mustakallio KK (1989) Topical cyclosporine and contact dermatitis in guinea pig and man. Arch Dermatol 125: 568
Lin CS, Boltz RC, Siekierka JJ, Sigal NH (1991) FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 133: 269–284
Lui J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 cmplexes. Cell 66: 807–815
Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13: 136–142
Abu-Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, Starzl TE (1991) FK506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23: 3322–3324
Meingassner JG, Stütz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98: 851–855
Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S (1992) Inhibition of contact allergy reactions by topical FK506. Lancet 340: 556
Maurer T, Kimber I (1991) Draining lymph node cell activation in guinea pigs: comparisons with the murine local lymph node assay. Toxicology 69: 209–218
Hermann RC, Taylor RS, Ellis CN, Williams NA, Weiner ND, Flynn GL, Annesley TM, Voorhees JJ (1988) Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1: 246–249
Surber C, Itin P, Büchner S (1992) Clinical controversy on the effect of topical ciclosporin: what is the target site? Dermatology 185: 242–245
Eisen D, Ellis CN, Duell EA, Griffiths CEM, Voorhees JJ (1990) Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N Engl J Med 323: 290–294
Mizoguchi M, Kawaguchi K, Ohsuga Y, Ikari Y, Yanagawa A, Mizushima Y (1992) Cyclosporin ointment for psoriasis and atopic dermatitis. Lancet 339: 1120
Powles AV, Baker BS, McFadden J, Rutman AJ, Griffiths CEM, Fry L, Valdimarsson H (1988) Intralesional injection of cyclosporin in psoriasis. Lancet II: 537
Ho VC, Griffiths CEM, Ellis CN, Gupta AK, McCuaig C, Nickoloff BJ, Cooper KD, Hamilton TA, Voorhees JJ (1990) Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunological, and pharmacokinetic study. J Am Acad Dermatol 22: 94–100
Burns MK, Ellis CN, Eisen D, Duell E, Griffiths CEM, Annesley TM, Hamilton TA, Birnbaum JE, Voorhees JJ (1992) Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. Arch Dermatol 128: 786–790
Nakagawa S, Oka D, Jinno Y, Takei Y, Bang D, Ueki H (1988) Topical application of cyclosporine on guinea pig allergic contact dermatitis. Arch Dermatol 124: 907–910
Meingassner JG, Stütz A (1992) Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 99: 486–489
Tocci MJ, Matkovitch DA, Collies KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143: 718–726
Knight SC, Roberts M, Macatonia SE, Edwards AJ (1988) Blocking of acquisition and presentation of antigen by dendritic cells with cyclosporine. Studies with fluorescein isothiocyanate. Transplantation 46: 48S-53S
Lauerma AI, Lee CH, Homey B, Bloom E, Maibach HI (1993) Topical cis-urocanic acid suppresses local lymph node activation during induction of contact hypersensitivity. J Invest Dermatol 110: 596A
Reeve VE, Greenoak GE, Canfield PJ, Boehm-Wilcox C, Gallagher CH (1989) Topical urocanic acid enhances UV-induced tumour yield and malignancy in the hairless mouse. Photochem Photobiol 49: 459–464
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lauerma, A.I., Stein, B.D., Homey, B. et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 286, 337–340 (1994). https://doi.org/10.1007/BF00402225
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00402225